ProPhase Labs, Inc. Amortization of Debt Issuance Costs and Discounts
ProPhase Labs, Inc. (PRPH) reported Amortization of Debt Issuance Costs and Discounts of $1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-19
- ProPhase Labs, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $760.00K, a 59.33% increase year-over-year.
- ProPhase Labs, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $476.00K, a 27.96% increase year-over-year.
- ProPhase Labs, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-06-30 was $477.00K.
- ProPhase Labs, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-03-31 was $372.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month |
|---|---|---|
| 2026-06-30 | $760.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $1.24M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $476.00K 10-Q/A · filed 2026-07-09 | |
| 2025-06-30 | $477.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $849.00K 10-Q · filed 2026-08-19 |
| 2025-03-31 | $372.00K 10-Q/A · filed 2026-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |